{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T07:22:22Z","timestamp":1781248942330,"version":"3.54.1"},"reference-count":23,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.clbc.2025.05.002","type":"journal-article","created":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T11:13:02Z","timestamp":1747307582000},"page":"e945-e953.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Real-World 5-Year Outcomes of Patients Treated With the Adjuvant Paclitaxel Trastuzumab (APT) Regimen for Stage I HER2-Positive Early Breast Cancer: A Retrospective International Study"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5847-7192","authenticated-orcid":false,"given":"Soraia","family":"Lobo-Martins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronique","family":"Debien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Agostinetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Sirico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giselle de Souza","family":"Carvalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Molinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata Colombo","family":"Bonadio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Bergmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiano de P\u00e1dua","family":"Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Testa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Nishimuni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Jo\u00e3o Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel Kamei","family":"Guimar\u00e3es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ugo","family":"De Giorgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Bines","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donatienne","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois P.","family":"Duhoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Barchiesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Lambertini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Piccart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evandro","family":"de Azambuja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.clbc.2025.05.002_bib0001","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","article-title":"Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"35","author":"Loibl","year":"2024","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.clbc.2025.05.002_bib0002","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/annonc\/mdz173","article-title":"Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Cardoso","year":"2019","journal-title":"Ann Oncol"},{"issue":"14","key":"10.1016\/j.clbc.2025.05.002_bib0003","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","article-title":"Adjuvant trastuzumab in HER2-positive breast cancer","volume":"365","author":"Slamon","year":"2011","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.clbc.2025.05.002_bib0004","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/S1470-2045(21)00288-6","article-title":"Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials","volume":"22","author":"Bradley","year":"2021","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.clbc.2025.05.002_bib0005","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2025.05.002_bib0006","unstructured":"NCCN. Guidelines detail. Accessed December 11, 2023. https:\/\/www.nccn.org\/guidelines\/guidelines-detail"},{"issue":"2","key":"10.1016\/j.clbc.2025.05.002_bib0007","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1406281","article-title":"Adjuvant Paclitaxel and Trastuzumab for node-negative, HER2-positive breast cancer","volume":"372","author":"Tolaney","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clbc.2025.05.002_bib0008","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.19.00066","article-title":"Seven-year follow-up analysis of Adjuvant Paclitaxel and Trastuzumab trial for node-negative, Human epidermal growth factor receptor 2\u2013Positive breast cancer","author":"Tolaney","year":"2019","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.clbc.2025.05.002_bib0009","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S1470-2045(23)00051-7","article-title":"Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial","volume":"24","author":"Tolaney","year":"2023","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.clbc.2025.05.002_bib0010","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.annonc.2023.10.001","article-title":"ESMO guidance for reporting oncology real-world evidence (GROW)","volume":"34","author":"Castelo-Branco","year":"2023","journal-title":"Ann Oncol"},{"issue":"23","key":"10.1016\/j.clbc.2025.05.002_bib0011","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMsb1609216","article-title":"Real-world evidence \u2014what is it and what can it tell us?","volume":"375","author":"Sherman Rachel","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clbc.2025.05.002_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2023.104089","article-title":"Real-world clinical outcomes of patients with stage I HER2-positive breast cancer treated with adjuvant paclitaxel and trastuzumab","volume":"190","author":"Debien","year":"2023","journal-title":"Crit Rev Oncol Hematol"},{"issue":"12","key":"10.1016\/j.clbc.2025.05.002_bib0013","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1016\/j.annonc.2020.08.2106","article-title":"A Food and Drug Administration analysis of survival outcomes comparing the Adjuvant Paclitaxel and Trastuzumab trial with an external control from historical clinical trials","volume":"31","author":"Amiri-Kordestani","year":"2020","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.clbc.2025.05.002_bib0014","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s10549-015-3426-z","article-title":"Chemotherapy-related amenorrhea after adjuvant paclitaxel\u2013trastuzumab (APT trial)","volume":"151","author":"Ruddy","year":"2015","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.clbc.2025.05.002_bib0015","doi-asserted-by":"crossref","first-page":"33","DOI":"10.6004\/jnccn.2022.7065","article-title":"Impact of anti-HER2 therapy alone and with weekly Paclitaxel on the ovarian reserve of young women with HER2-positive breast cancer","volume":"21","author":"Lambertini","year":"2023","journal-title":"J Natl Comprehen Cancer Netw"},{"issue":"2","key":"10.1016\/j.clbc.2025.05.002_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100088","article-title":"Adjuvant endocrine therapy in HER2-positive breast cancer patients: systematic review and meta-analysis","volume":"6","author":"Peleg Hasson","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.clbc.2025.05.002_bib0017","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ejca.2017.03.033","article-title":"HER2 status predicts for upfront AI benefit: a TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2","volume":"79","author":"Bartlett","year":"2017","journal-title":"Eur J Cancer"},{"issue":"12","key":"10.1016\/j.clbc.2025.05.002_bib0018","doi-asserted-by":"crossref","first-page":"e7317","DOI":"10.1002\/cam4.7317","article-title":"Real-world treatment patterns of adjuvant endocrine therapy and ovarian suppression in premenopausal HR+\/HER2+ breast cancer","volume":"13","author":"Sukumar","year":"2024","journal-title":"Cancer Med"},{"issue":"4","key":"10.1016\/j.clbc.2025.05.002_bib0019","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1093\/annonc\/mdz047","article-title":"The immune profile of small HER2-positive breast cancers: a secondary analysis from the APT trial","volume":"30","author":"Barroso-Sousa","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2025.05.002_bib0020","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ejca.2022.01.031","volume":"166","author":"Gelber","year":"2022","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.clbc.2025.05.002_bib0021","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1093\/jnci\/djab057","article-title":"Tumor cellularity and infiltrating lymphocytes as a survival surrogate in HER2-positive breast cancer","volume":"114","author":"Chic","year":"2022","journal-title":"JNCI"},{"key":"10.1016\/j.clbc.2025.05.002_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103801","article-title":"Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer","volume":"75","author":"Prat","year":"2022","journal-title":"EBioMedicine"},{"issue":"10437","key":"10.1016\/j.clbc.2025.05.002_bib0023","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1016\/S0140-6736(24)00054-0","article-title":"3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial","volume":"403","author":"P\u00e9rez-Garc\u00eda","year":"2024","journal-title":"Lancet"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820925001156?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820925001156?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T20:56:28Z","timestamp":1762548988000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820925001156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":23,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S1526820925001156"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2025.05.002","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-World 5-Year Outcomes of Patients Treated With the Adjuvant Paclitaxel Trastuzumab (APT) Regimen for Stage I HER2-Positive Early Breast Cancer: A Retrospective International Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2025.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}